Alterity Therapeutics (ASX:ATH): CEO Dr David Stamler on ATH434, FDA Phase 3 & the Quest to Treat Multiple System Atrophy
Can Alterity Therapeutics (ASX:ATH) become the first company to develop a disease-modifying treatment for Multiple System Atrophy (MSA)? In this episode of the Homodeus Research Podcast, Dr David Stamler, Managing Director & CEO of Alterity Therapeutics, discusses the company's lead therapeutic candidate, ATH434, and the latest progress toward a pivotal Phase 3 clinical trial following alignment with the U.S. Food and Drug Administration (FDA). Dr Stamler explains the underlying science behind ATH434, how abnormal iron accumulation contributes to neurodegenerative disease, and why Alterity…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.